23rd, March 2023

2023 World Tuberculosis Day Commemoration in KNCV Nigeria Supported States

Group photograph of the NTBLCP, KNCV, and implementing partners at the 2023 World TB Day road walk in Abuja.

World Tuberculosis Day (WTBD) is an annual event observed on March 24th  to raise public awareness about the devastating
health, the social and economic impact of tuberculosis (TB) and urge acceleration of efforts to end the global TB
epidemic. The date marks the day in 1882 when Dr. Robert Koch announced that he had discovered the bacterium
that causes TB, which opened the way towards diagnosing and curing this disease.

The theme for this year’s World TB Day is “Yes! We Can End TB.” The theme brings attention to tuberculosis (TB)
and that it is in our collective power to end TB by 2030 and therefore reach the SDG goals. Stakeholders decided
to choose a theme that brings hope and builds on the amazing work done in 2022 by many TB High Burden
Countries to recover from the impact of the COVID epidemic and to ensure access to new diagnostics, new treatment
regimens, digital technology, and artificial intelligence (AI) for the TB response. It also centers on the increased
engagement of those affected by TB, communities, and civil society who are leading the movement toward
ending this disease.

To mark this year’s World TB Day, the National Tuberculosis and leprosy program (NTBLCP) in collaboration with Donors, and implementing partners organized activities like Road walks, Press briefings, media appearances, and TB outreach across the 36 states in Nigeria.
KNCV Nigeria participated in these planned activities across the 14 states in Nigeria where we work.

15th, March 2022

The ace project

26TH, AUGUST 2021

The Nigeria DATs Project

Figure: Map of the eight states implementing DATs Project in Nigeria

The Digital Adherence Technologies (DATs) Project is funded by Stop TB Partnership/UNOPS (United Nations Office for Project Services) and implemented by KNCV TB Foundation Nigeria with a consortium of partners – KNCV Tuberculosis Foundation Netherlands and Interra Networks. The DATs project is aimed at comprehensive introduction of digital adherence technologies to support tuberculosis treatment across eight states in Nigeria: Akwa Ibom, Anambra, Benue, Imo, Kaduna, Kano, Nasarawa and Rivers through two intervention models:

  • 99DOTS medication labels – Use medication labels that contain a unique single 3-digit code and the country SMS short code number to track records of daily drug intake by TB patients.
  • VOT (Video-observed Therapy) – Use SureAdhere mobile app to record videos of drug intake by TB patients, enabling remote adherence monitoring through video technology by the Healthcare workers.

The project is the first TB treatment adherence technology to be implemented within the National TB program in Nigeria. It is focused on an integrated deployment approach, with different DAT options for patients and one unified application for the healthcare worker. The different DAT model helps to remind patients to take their medications, facilitate digital observation of pill-taking, compile dosing histories, triage patients based on their level of adherence, thereby facilitating the provision of individualized care by the TB program based on patients risks. The duration of the project is one year.




8th, AUGUST 2021


Dr. Bethrand Odume
Executive Director KNCV Nigeria

It has truly been an awesome five years of teamwork. I would like to express my sincere gratitude to the fantastic staff of KNCV Nigeria for the superb work done in the past five years – including during the global crisis that has recently emerged. The KNCV Board and all our partners have been very supportive all these years. The drive of our staff has been phenomenal and their commitment to fulfilling our vision and mission is beyond question. I know that we will continue to ensure that we find the missing TB cases in 14 states where we work in Nigeria as we strive to see a Nigeria free of tuberculosis. Our gratitude also goes to our funder, USAID for the resources as well as their technical guidance and to state TB program and facilities where we work. To the National TB Programme, we are grateful for their leadership and continued collaboration. KNCV Tuberculosis Foundation Nigeria is a local non-profit organization dedicated to the fight against tuberculosis (TB), the deadliest infectious disease in Nigeria. We are a national center of excellence for TB control that promotes effective, efficient, innovative, and sustainable tuberculosis control strategies in a national context. We opened our doors officially in Nigeria on the 8th of August 2016. It has been an awesome 5 years of teamwork, from the Challenge TB project to the USAID-funded WASP project and currently the USAID TB LON Regions 1 & 2 projects. The impactful TB control interventions in Nigeria are beyond question, through the years we haven’t lost sight of our vision to see a Nigeria free of Tuberculosis. It is with great pleasure that we announce and celebrate our 5th year Anniversary of impactful TB control interventions in Nigeria.

MAY, 2021


BPaL Regimen

Nigeria is the first country in West Africa to provide people with tuberculosis (TB) access to the groundbreaking new BPaL treatment under operational research conditions. This six-month, three-drug,  oral treatment is meant for people with advanced forms of drug resistant TB and is expected to have a higher success rate than previous treatments with 4-6 medicines which lasted at least 18 months.

The BPaL regimen (consisting of the drugs pretomanid, bedaquiline and linezolid) was developed by TB Alliance and is implemented in Nigeria by the National TB Program (NTP), with support from KNCV Tuberculosis Foundation (KNCV).

“We are excited about this novel treatment option which will hopefully present much relief to our patients. Winning the battle against tuberculosis remains our core mission as KNCV”
Dr. Victor Falokun
KNCV Project Manager, BPaL Nigeria

The BPaL regimen has been approved by the U.S Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Drug Controller General of India and recommended by the WHO under operational research conditions.

“The BPaL operational research is an intervention coming in at the right time to alleviate the suffering experienced by patients managed using the individualized regimen of 18 months with injectables. This will go a long way to provide quality treatment care and support for DR-TB patients across the country”
Dr. Babawale Victor
TB Specialist and Research Coordinator (NTBLCP)
The medical team at ATBUTH preparing to administer the BPaL regimen

New hope for people with drug resistant TB

Nigeria is ranked seventh out of the 30 highest burden countries for tuberculosis and second in Africa. In the year 2019, an estimated 440,000 new cases occurred (of these, 46,000 were also HIV-positive) 384 Laboratory confirmed cases of MDR/DR-TB and 16 Laboratory confirmed cases of XDR TB and about 150,000 Nigerians died from tuberculosis (TB) according to WHO.

TB accounts for more than 10% of all deaths in Nigeria. Every hour, nearly 30 people die from the disease, despite effective treatments being available.

Most people can be cured of TB with a standard, inexpensive treatment. However, with XDR-TB conventional drugs do not work. Treatment is much longer (18 months) and less effective. According to the WHO, the cure rate of XDR-TB worldwide is only 57 percent as of 2020. However the new BPaL regimen (6 months, without injections) has shown a cure rate of 90 percent in clinical trials, according to Phase 3 trial results published in the New England Journal of Medicine.

BPaL roll-out and scale-up

The official roll- out in Nigeria started second week of April in Bauchi state with three other states namely, Lagos, Adamawa and Kano to follow.

Patient Testimonial

Ruth Iliya

Rika Iliya, who was first diagnosed in January 2021 is the first TB patient in Nigeria to be treated with the new, ground-breaking TB treatment: the BPaL regimen. This treatment for people with extensively drug-resistant tuberculosis (XDR TB) is much shorter than previous treatments. Painful, daily injections are no longer necessary. Above all, BPaL is expected to have a much higher success rate. This brings new hope to patients with this form of TB.

Ruth with the KNCV team, NTBLCP team and her Doctors at ATBUTH DR-TB Treatment Center during the BPaL enrollment

“I was referred to Abubakar Tafawa Balewa University Teaching Hospital (ATBUTH) from FCT TBLCP in Abuja where I had been on other treatment drugs but the weakness and coughing continued,” she says.

The doctor at ATBUTH Bauchi diagnosed XDR-TB and Ruth was admitted immediately. Prior to her been diagnosed, Ruth planned to write the West African Examinations Council (WAEC) in Bauchi. This examination is a graduation certificate awarded to most students in Nigeria. This she will do while living with her uncle in Bauchi since her parents will not be able to stay with her all through the exam period in another state due to their jobs; unfortunately, she became ill.  Her uncle is presently her guardian in Bauchi while she is receiving treatment.

I can’t wait to get better and return to school. I do not want to miss my graduation examination” Ruth says.

But at the same time, she is hopeful.

Administration of the BPaL drug by Dr. Jacob Dunga, Internal Medicine Specialist and Research Clinician at ATBUTH

I feel so much better after starting the drugs last week, I am regaining my strength day by day”.

The 17-year-old High school student is now enrolled on BPaL and grateful that she has access to this new treatment.